Literature DB >> 29582127

Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) with Haematuria in the Absence of an Upper Urinary Tract Pathology.

Charles R Tapping1, Andrew Macdonald2, Mo Hadi2, Chloe Mortensen2, Jeremy Crew3, Andrew Protheroe4, Mark W Little2, Phil Boardman2.   

Abstract

PURPOSE: To assess the effectiveness of prostate artery embolization (PAE) in the control of haematuria and in patients with benign prostatic hyperplasia (BPH) and normal upper urinary tracts. SUBJECTS/PATIENTS: Twelve consecutive patients with haematuria were included in the prospective study. All patients had prior imaging and cystoscopy to exclude other causes of haematuria. Patients prostate arteries were embolized with particles (200-500 μm), and they were followed up at 3, 12 and 18 months following the procedure. QOL questionnaires, IPSS, IIEF and clinical review were all employed to assess the success of the treatment. To allow useful comparison, patients were age- and prostate volume-matched and compared to patients treated with PAE for BPH without haematuria.
RESULTS: All 12/12 cases were technically successful with bilateral PAE being performed. All cases of haematuria resolved by the 3-month follow-up (100%). There was one case of recurrence during the 12-month follow-up (overall clinical success at 18 months 92%). This was due to over anticoagulation and ceased once corrected. There was a reduction in lower urinary tract symptoms noted by improvements in QOL indices, IPSS and IIEF. There was continued success even if the patient was subsequently anticoagulated. There was no associated sexual dysfunction. There was more prostatic arterial branching and volume of embolic required to achieve stasis in BPH and haematuria than in BPH alone (p < 0.05).
CONCLUSION: PAE is a very useful technique for controlling the quite debilitating condition of haematuria in patients with visible haematuria of prostatic origin. Controlling haematuria and BPH allows a significant improvement in QOL.

Entities:  

Keywords:  Benign prostatic hyperplasia; Haematuria; Lower urinary tract symptoms; Prostate artery embolization

Mesh:

Year:  2018        PMID: 29582127     DOI: 10.1007/s00270-018-1941-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

1.  Prostatic Artery Embolization: Indications, Preparation, Techniques, Imaging Evaluation, Reporting, and Complications.

Authors:  Ubenicio Silveira Dias; Maurício Ruettimann Liberato de Moura; Publio Cesar Cavalcante Viana; André Moreira de Assis; Antônio Sérgio Zanfred Marcelino; Airton Mota Moreira; Claudia Costa Leite; Giovanni Guido Cerri; Francisco Cesar Carnevale; Natally Horvat
Journal:  Radiographics       Date:  2021-08-20       Impact factor: 6.312

Review 2.  The application of prostate artery embolization in the management of intractable prostate bleeding.

Authors:  Agata Stężewska; Magdalena Stężewska; Bartosz Żabicki; Maciej Salagierski
Journal:  Cent European J Urol       Date:  2020-09-15

Review 3.  Modern imaging and image-guided treatments of the prostate gland: MR and ablation for cancer and prostatic artery embolization for benign prostatic hyperplasia.

Authors:  João Lopes Dias; Tiago Bilhim
Journal:  BJR Open       Date:  2019-08-14

4.  Prostate artery embolization in a patient with left ventricular assist device.

Authors:  Jay Vasani; Sanghun Kim; Kieran Hynes; Charles Pound; Issam Kably
Journal:  Urol Case Rep       Date:  2021-01-29

5.  Prostatic artery embolization in men with severe hemophilia a: a case report of two patients.

Authors:  Petra Svarc; Peter Kampmann; Lars Lönn; Martin Andreas Røder
Journal:  CVIR Endovasc       Date:  2022-04-21

6.  Safety and efficacy of transcatheter arterial embolization for management of refractory hematuria of prostatic origin.

Authors:  Jinlong Zhang; Quanyu Wang; Hongwei Zhao; Bing Yuan; Xuedong Sun; Yang Guan; Zhuting Fang; Maoqiang Wang
Journal:  J Interv Med       Date:  2022-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.